Dr. George Somlo is a cum laude graduate of the University of Semmelweis Medical School in Budapest, Hungary. He completed his fellowship at the Department of Virus-Vaccine Control at the National Institute of Public Health and after a short stay in the Department of Head and Neck Surgery at the National Cancer Institute in Budapest, Hungary, he moved to California. Following internal medicine training in the University of California, Irvine-Long Beach VA program, he completed fellowship training in medical oncology, hematology, and bone marrow transplantation (BMT) at the City of Hope National Medical Center.
At City of Hope, Dr. Somlo served as director, Breast Oncology, co-director of the Breast Cancer Program and as director of the Multiple Myeloma Program. He is currently professor with joint appointments in the Departments of Medical Oncology & Therapeutics Research and Hematology & Hematopoietic Cell Transplantation. Among his many institutional functions, he is President-Elect of the Medical Staff, and a member of the Board of Directors, City of Hope Medical Center.
Dr. Somlo’s clinical/translational research interests extend beyond a single discipline. He is a longtime panel member of the NCCN breast cancer and multiple myeloma guideline committees. He has been actively participating in a variety of ASCO committees focusing on breast cancer, and has been involved with guideline development for growth factors. He is a Multiple Myeloma Steering Committee Member in the BMT-Clinical Trial Network.
Dr. Somlo has been a member of grant review panels (DOD, NCCN, Komen, NCI of the Netherlands and Singapore), and reviewer of many prestigious journals including the NEJM, JAMA, Clinical Cancer Research, Lancet Oncology, Journal of Clinical Oncology, and many others.
Areas of his funded active research include identifying molecular targets and profiles responsible for resistance in breast cancer, whether in primary or metastatic, or circulating tumor cell “compartments” in patients with locally advanced/inflammatory and stage IV breast cancer.
Dr. Somlo is particularly interested in collaborations focusing on triple negative breast cancer and overcoming breast cancer stem cell resistance in the preclinical and subsequently clinical settings. He is co-leader for the Breast Cancer Program of the NCI-contract-supported California Cancer Center Consortium (CCCP); a member of the leadership team in the SWOG Breast Committee; and principal or co-principal investigator for trials ranging from institutional phase II HER2-targeting and triple-negative breast cancer-focused neoadjuvant studies and co-leading a PARP-inhibitor trial in BRCA carriers in the NCI-contracted California Cancer Consortium. He is the principal investigator of a phase III SWOG cooperative group trial aimed to define better therapies for patients with stage IV hormone-receptor positive breast cancer.
Dr. Somlo is also actively involved as principal or co-principal investigator in institutional, cooperative group, and industry-sponsored phase I-III trials in multiple myeloma, focusing on the role of single vs. tandem autologous stem cell transplantation, incorporation of total marrow irradiation into transplant regimens, and testing novel –including immunotherapeutic-agents.
Dr. Somlo has published over 200 peer-reviewed papers and book chapters, and is funded by the NIH, SWOG-Hope Foundation, and DOD.
Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.